Atopic Dermatitis Market FORECAST 2019-2027
• The Atopic Dermatitis Drugs global market is growing at 4.66% of CAGR over the forecasting years. • Growing incidences of allergies due to particular foods is the major factor augmenting the market growth globally.
• Atopic Dermatitis is a skin disease also known as chronic eczematous. The symptoms of this disease vary person to person. However, some of its common symptoms are inflamed and itchy skin that causes crackling, minute blisters, swelling, scaling, and crusting. • The global Atopic Dermatitis drugs market comprise of two segments route of administration and drug class. • The topical segment holds the highest share in the Atopic Dermatitis Drugs route of administration market. • The interleukin inhibitor segment is anticipated to generate the highest revenue in the Atopic Dermatitis drug class market. • The global Atopic Dermatitis Drugs market is highly generic which creates a lot of challenges in the growth of the market globally.
“The Atopic Dermatitis Drugs global market is growing at 4.66% of CAGR over the forecasting years.�
During the forecasting years, the Atopic Dermatitis Drugs market in North America is proliferating at a CAGR of 4.06%.
Europe Atopic dermatitis drugs market continues to escalate at 3.20% of CAGR over the forecasting years.
The Atopic Dermatitis Drugs market in APAC region is anticipated to evolve at a CAGR of 7.46% over the estimated period 2018-2026.
The established players in the market are Allergan Plc., Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag, BristolMyers Squibb, Stiefel Laboratories Inc., Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan), Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, and Valent Pharmaceutical Inc.